RAPT director granted 4,956 RSUs as stock award

RAPT Therapeutics director Michael F. Giordano reported a stock-based compensation grant.

Accepted by SEC EDGAR 02/02/2026 - 05:56 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

RAPT Therapeutics director Michael F. Giordano reported a stock-based compensation grant. On 01/30/2026 he received 4,956 shares of common stock at a price of $0, reported as directly owned after the transaction.

The footnote explains this represents the annual grant of restricted stock units under the company’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs fully vest on the first anniversary of the grant date, and each unit will deliver one share of common stock upon vesting.

Insider Trade Summary

Grant/Award: 4,956 shares

Grant/Award 1 txn

Insider Giordano Michael F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,956	$0.00	$0.00

Holdings After Transaction: Common Stock — 4,956 shares (Direct)

Holdings Before and After: Common Stock, 0 to 4,956 shares (Direct)

Footnotes (1)

1. F1. Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Michael F. Giordano report for RAPT (RAPT)?

Michael F. Giordano reported receiving 4,956 shares of RAPT common stock on January 30, 2026. The shares stem from an annual restricted stock unit grant under the non-employee director compensation policy and were reported at a price of $0 per share as stock-based compensation.

How many RSUs did the RAPT director receive and when do they vest?

He received 4,956 restricted stock units as his annual director equity award. According to the disclosure, these RSUs fully vest on the first anniversary of the January 30, 2026 grant date, after which each unit converts into one share of RAPT common stock.

Was cash paid for the 4,956 RAPT shares reported in this Form 4?

No cash was paid for these shares; the transaction price is listed as $0 per share. The grant represents stock-based compensation issued under RAPT Therapeutics’ Amended & Restated Non-Employee Director Compensation Policy for its non-employee directors.

What is Michael F. Giordano’s role at RAPT Therapeutics, Inc. (RAPT)?

Michael F. Giordano is identified as a director of RAPT Therapeutics, Inc. The Form 4 indicates his relationship to the issuer by checking the “Director” box, with no officer role or 10% owner status selected in the reporting person information.

How many RAPT shares does Giordano own after this reported transaction?

Following the reported grant, he beneficially owns 4,956 shares of RAPT common stock. The filing shows this amount as directly owned after the transaction, reflecting the full number of shares associated with the restricted stock unit award.

What compensation policy governs this RAPT director’s RSU grant?

The grant is made under RAPT Therapeutics’ Amended & Restated Non-Employee Director Compensation Policy. The filing notes this policy is currently in effect and provides for an annual RSU grant that fully vests one year after the grant date for non-employee directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Giordano Michael F

(Last) (First) (Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	01/30/2026		A		4,956	A	$0	4,956	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.

	/s/ Rodney Young, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.